Table 2.
Characteristics and outcomes of health-facility-based active yaws incidence studies
| Period of study | Country | Location | Target population | Case ascertainment | New cases (at-risk population) | Incidence, cases per 1000 population-years (95% CI) | |
|---|---|---|---|---|---|---|---|
| Africa | |||||||
| Toure et al (2007)11 | 2000 | Côte d'Ivoire | Nationwide | Children and adults | Clinical | 9212 (15 882 758) | 0·58 (0·57–0·59) |
| Konan et al (2013)12 | 2011 | Côte d'Ivoire | Nationwide | Children and adults | Clinical | 3343 (22 594 212) | 0·15 (0·14–0·15) |
| Edorh et al (1994)15 | 1991 | Togo | Nationwide | School children | Clinical | 3750 (3 787 000) | 0·99 (0·96–1·02) |
| Nnoruka (2005)17 | 1999–2001 | Nigeria | Enugu Hospital | Children and adults | Clinical | 0 (2871) | 0·00 (0·00–1·28) |
| Western Pacific | |||||||
| Manning and Ogle (2002)21 | 2000–01 | Papua New Guinea | Port Moresby | Children and adults | RPR and TPHA | 494 (20 000) | 24·70 (22·59–26·95) |
| Mitja et al (2011)22 | 2009 | Papua New Guinea | Lihir Island | School children | RPR and TPHA | 138 (5 400) | 25·56 (21·51–30·12) |
| Ministry of Health, Solomon Islands (2013)23 | 2012 | Solomon Islands | Nationwide | Children and adults | Clinical | 12 372 (515 870) | 23·98 (23·57–24·40) |
RPR=rapid plasma reagin. TPHA=Treponema pallidum haemagglutination.